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STUDY PROTOCOL Open Access
Cognitive behavioural therapy for the
management of inflammatory bowel
disease-fatigue with a nested qualitative
element: study protocol for a randomised
controlled trial
Micol Artom* , Wladyslawa Czuber-Dochan, Jackie Sturt and Christine Norton
Abstract
Background: Fatigue is one of the most prevalent and burdensome symptoms for patients with inflammatory
bowel disease (IBD). Although fatigue increases during periods of inflammation, for some patients it persists when
disease is in remission. Compared to other long-term conditions where fatigue has been extensively researched,
optimal management of fatigue in patients with IBD is unknown and fatigue has rarely been the primary outcome
in intervention studies. To date, interventions for the management of IBD-fatigue are sparse, have short-term effects
and have not been implemented within the existing health system. There is a need to integrate current best
evidence across different conditions, patient experience and clinical expertise in order to develop interventions for
IBD-fatigue management that are feasible and effective. Modifying an existing intervention for patients with
multiple sclerosis, this study aims to assess the feasibility and initial estimates of efficacy of a cognitive behavioural
therapy (CBT) intervention for the management of fatigue in patients with IBD.
Methods: The study will be a two-arm pilot randomised controlled trial. Patients will be recruited from one
outpatient IBD clinic and randomised individually to either: Group 1 (CBT manual for the management of fatigue,
one 60-min session and seven 30-min telephone/Skype sessions with a therapist over an eight-week period); or
Group 2 (fatigue information sheet to use without therapist help). Self-reported IBD-fatigue (Inflammatory Bowel
Disease-Fatigue Scale) and IBD-quality of life (United Kingdom Inflammatory Bowel Disease Questionnaire) and
self-reported disease activity will be collected at baseline, three, six and 12 months post randomisation. Illness
perceptions, daytime sleepiness, anxiety and depression explanatory variables will be collected only at three
months post randomisation. Clinical and sociodemographic data will be retrieved from the patients’ medical notes.
A nested qualitative study will evaluate patient and therapist experience, and healthcare professionals’ perceptions
of the intervention.
Discussion: The study will provide evidence of the feasibility and initial estimates of efficacy of a CBT intervention
for the management of fatigue in patients with IBD. Quantitative and qualitative findings from the study will
contribute to the development and implementation of a large-scale randomised controlled trial assessing the
efficacy of CBT interventions for IBD-fatigue.
Trial registration: ISRCTN Registry, ISRCTN17917944. Registered on 2 September 2016.
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Background
Inflammatory bowel disease (IBD) mainly encompasses
two related but distinct conditions of the gastrointestinal
tract: ulcerative colitis (UC) and Crohn’s disease (CD).
UC is characterised by diffuse mucosal inflammation
limited to the rectum and colon. CD is characterised by
patchy, transmural inflammation, affecting any part of
the gastrointestinal tract from the mouth to the anus
[1–3]. IBD is a lifelong condition, which frequently
presents in adolescence or young adulthood and follows
an unpredictable relapsing and remitting course. The
prevalence of IBD in the United Kingdom (UK) is about
300,000 with CD and UC affecting 5–10 and 10–20 new
patients, respectively, per 100,000 people per year [4].
Patients with IBD are affected by a number of symp-
toms, undergo lifelong pharmacological treatment and
have an increased risk of malignancy [5, 6]. Due to the
severity of IBD, psychological distress is also common
[7], with prevalence of symptoms of depression and
anxiety around 22% and 35%, respectively [8]. As IBD
has an early life onset, a chronic nature and does not
generally shorten lifespan, addressing how patients deal
with their disease is an important aspect of care [9]. The
current standard care in IBD treatment is aimed at man-
aging the inflammatory response during flare episodes
and maintaining remission, with an emphasis on adher-
ing to a regular medication regime [10]. However, mani-
festations of IBD cannot be fully accounted for by
pathophysiology and the simple targeting of inflamma-
tion does not necessarily reduce the symptoms affecting
patients the most [11–13]. In line with the international
expert consensus of the recent Therapeutic Targets in
Inflammatory Bowel Disease (STRIDE) initiative [14] on
treatment targets for IBD, it is therefore important to
shift from management of IBD aimed solely at achieving
endoscopic remission to also evaluating patient reported
outcomes (PROs) with the ultimate goal of improving
patients’ quality of life (QoL) [15].
Fatigue is a common and predominant concern for
patients with IBD, experienced by 44–86% of patients
with active disease and 22–41% of patients in remission
[16]. Fatigue is a complex, multifactorial and multidi-
mensional phenomenon, which has been described as a
‘persistent overwhelming sense of tiredness, weakness,
or exhaustion’ [17], that can be mental, physical or both
[18]. Unlike everyday tiredness, fatigue is often unrelieved
by sleep or rest [19], can have a substantial negative impact
on patients’ QoL [20–23] and it may limit patients in their
everyday lives [24]. Although fatigue understandably
increases during periods of inflammation, for some
patients it persists when disease is in clinical and
endoscopic remission [25].
Despite the pervasiveness of fatigue as a chief complaint
in IBD patients [23], it is only identified and treated in a
relatively small proportion of those affected [26]. The
causes of fatigue in IBD are not well understood by either
patients [27] or healthcare professionals (HCPs) [28].
Disease activity [22, 29–31], anaemia [32–34] and inflam-
mation [32] have been found to be predictive of fatigue,
yet there is a considerable number of IBD patients with
no apparent physiological underpinnings for their fatigue
[35]. Apart from a consistent relationship with disease
activity, IBD-fatigue has been linked to psychosocial
factors such as low mood [31, 36, 37] and sleep problems
[29, 31, 37, 38]. However, most previous research has
focused on the relationship between fatigue and clinical
variables. The ways in which clinical variables and poten-
tially modifiable factors interact with each other in fatigue
has rarely been explored [39].
The complex aetiology of fatigue [16], its subjective
nature [40] and the lack of objective ‘gold standard’ to
measure fatigue [41], also add to the challenge of develop-
ing suitable and effective management methods. Optimal
management of fatigue in patients with IBD is unknown
and fatigue has rarely been the primary outcome in inter-
vention studies [42–45]. Pharmacological trials utilising
biologic therapy [46–48], thiamine [43] or ferumoxytol
[49] have shown potential benefits for fatigue. However,
these are contrasted by findings in observational studies
showing higher fatigue in patients taking biologic therapy
[23, 30, 31] and it is unclear whether these effects are due
to a reduction in inflammation or to a direct influence on
fatigue-signalling pathways [50]. Despite the known im-
portance of physical activity in IBD-fatigue [31, 51], the
only trial [45] examining the effect of advice to increase
physical activity provided inconclusive results. A few
psychosocial interventions, such as problem-solving,
solution focused therapy (SFT) [42, 44] and stress
management [52], have shown promising effects which
declined over time and studies included only a small
number of participants.
Stress management [52] has been compared with
conventional medical treatment in 45 patients with CD.
Self-directed stress management significantly reduced
tiredness post-treatment, at six-month and 12-month
follow-up. However, fatigue was measured with a symp-
tom diary rating devised by the authors and not with a
validated fatigue scale for the assessment of fatigue in
long-term conditions [41]. Moreover, fatigue was not the
primary outcome of the intervention, making the mech-
anisms of change difficult to assess. The efficacy of SFT
on fatigue and QoL was evaluated in 98 patients with
quiescent IBD [44]. After the intervention and at three-
month and six-month follow-up, the SFT group showed a
significantly greater reduction in fatigue and improvement
of QoL comparable to the care as usual group. Yet, the
effect was not maintained at nine months post interven-
tion. It is therefore important to design interventions with
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longer-term effect of reducing fatigue (with follow-up
assessments of a minimum of 12 months), in order to
determine whether positive effects of interventions can be
sustained over long periods of time, and if not, establish
the reasons for loss of response over time [53].
Compared to IBD, where fatigue has not been well de-
scribed, understood or managed [16], in other long-term
conditions fatigue has been extensively researched.
Drawing from evidence on fatigue in other chronic con-
ditions with relapsing and remitting trajectory, such as
multiple sclerosis (MS) and rheumatoid arthritis (RA),
can help to identify the mechanism in which psycho-
social and clinical factors interact with each other and
contribute to higher levels of fatigue, and identify types
of interventions for fatigue management in IBD patients.
A few fatigue treatment protocols based on cognitive-
behavioural models [54–56], employed in large-scale
randomised controlled trials (RCTs) in inflammatory
conditions (e.g. MS, RA) have found promising results
in fatigue reduction [57–59]. Although varying across
conditions and symptoms, cognitive-behavioural models
are based on the premise that symptoms are maintained
by maladaptive cognitive and behavioural factors [60].
Initially, primary disease factors, such as inflammation,
may trigger symptoms of fatigue. The ways in which
people react cognitively, emotionally and behaviourally
to their fatigue may perpetuate or worsen the symptoms
[54]. Consequently, altering cognitions, emotions and
behavioural responses in relation to fatigue through
cognitive-behavioural therapy (CBT) may improve clinical
and psychosocial outcomes [61, 62].
Van Kessel et al. [57] assessed the efficacy of delivering
CBT or relaxation training (RT) to 72 patients with MS
and found that the CBT group reported significantly
greater reductions in fatigue nine months post interven-
tion compared to the RT group. Thomas et al. [62–64]
compared six weekly sessions of group-based CBT with
current local practice in 164 patients with MS and found
statistically significant differences in fatigue severity in
favour of the intervention group four months and one
year post intervention. Similarly, in a two-arm, parallel
RCT in adults with RA, Hewlett et al. [58] compared six
weekly sessions and a consolidation session of group CBT
with self-management information in a 1-h didactic group
session. At 18 weeks from the intervention start, CBT par-
ticipants reported better scores than control participants
for fatigue impact and perceived fatigue severity.
For people with IBD, CBT has been utilised for a
variety of outcomes, including relapse reduction [65]
and perceived stress [66]. Six systematic reviews have
collectively appraised studies of psychological treatment for
IBD [67–72] with encouraging results. In the most recent
systematic review and meta-analysis [72] of RCTs compar-
ing psychological therapy with a control intervention or a
control treatment (14 studies), a significant difference in
depression scores and quality of life with psychological
therapy was observed at the end of therapy in patients with
quiescent disease. However, beneficial effects were lost at
the final point of follow-up. When assessing the effect of in-
dividual physiological therapies on quality of life, only CBT
had any significant beneficial effect. In a systematic review
of 17 studies, Goodhand et al. [68] concluded that CBT
was effective for mood disorders and improved QoL in pa-
tients with IBD. McCombie et al. [71] and Knowles et al.
[70] evaluated studies of the main types of psychological
treatment for IBD and found that CBT and its variants
most commonly contributed to positive outcomes as
compared to other psychotherapies (i.e. psychoeducation
and problem-solving therapy). CBT consistently resulted in
improved psychological distress, but with modest effects in
gastrointestinal symptoms these were not sustained over
time. However, these findings have to be interpreted in light
of limitations, including: time and travel burden for patients
attending face-to-face sessions; and high attrition rates and
low compliance issues for online interventions [73, 74].
There is a need to integrate current best evidence across
different conditions, patient experience and clinical ex-
pertise in order to develop interventions for IBD-fatigue
management that are feasible and effective [75]. Balancing
the insights from research and practice can maximise the
likelihood of interventions being feasible and acceptable,
and of treatment addressing important issues to patients
while overcoming previously identified limitations [76].
There is evidence from RCT interventions in other
long-term conditions [57–59] to suggest that modifying
maladaptive cognitions and behaviours through CBT
could be a viable option for the management of fatigue.
Drawing from interventions in other conditions can en-
hance the process of development of new evidence-based
management strategies in IBD without ‘reinventing the
wheel’ [77]. Previous quantitative [78, 79] and qualitative
studies [80] and systematic reviews [16, 39] showed
similarities between the perceived experience of fatigue
between different disease groups. Across conditions, fa-
tigue is closely related to relapse and more active disease
[81, 82] and similar physical and psychosocial factors
appear to be causing and exacerbating fatigue [80].
Additionally, the findings from our recent study [83] indi-
cate that the ways patients perceive, interpret and react to
fatigue symptoms in IBD is largely comparable to patients
with MS specifically [84]. Patients who have more negative
perceptions of fatigue, higher levels of all-or-nothing and
avoidance behaviours have significantly greater fatigue
scores compared to those with less negative cognitions
and behaviours in relation to their fatigue.
Based on these premises, the CBT intervention developed
by Van Kessel and colleagues [57] for MS was chosen as
the basis of our intervention study for IBD patients.
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Iterative work with both patients and HCPs working with
patients with IBD was then conducted in order to tailor the
intervention to IBD patients’ needs following the guidelines
on Patient and Public Involvement (PPI) involvement in
healthcare [85, 86]. An initial trial has shown promising re-
sults with patients with MS [57], has a strong theoretical
grounding in a CBT model [87] and has incorporated a
valuable and in-depth mediation analysis of processes of
change after the trial [88]. The intervention involved eight
weekly sessions of 50 min and covered: an introduction to
the CBT model of fatigue; activity scheduling; changing
unhelpful cognitions surrounding MS and fatigue; sleep hy-
giene and restoring sleep–wake cycles; managing negative
emotions; and the role of social support. In MS, calculated
effect sizes for fatigue from baseline to the end of treatment
were 3.03 for the CBT group and 1.83 for the RT group,
with clinically significant improvements in fatigue. Further-
more, in our study [83], negative perceptions of fatigue and
avoidance behaviours were identified in patients with IBD.
In MS patients in the trial [88] these same perceptions of
fatigue and avoidance behaviours improved significantly
more in the CBT than in the RT group. Changing negative
perceptions of fatigue mediated the decrease in severity of
fatigue [88]. Content of the intervention is described in
more detail in Van Kessel et al. [57].
As a result of the challenges inherent in evaluating
complex interventions such as CBT, the UK Medical Re-
search Council (MRC) Framework for the development
of complex intervention [89] recommends a stepwise
approach, with an early piloting phase prior to the de-
sign of a large-scale trial. Pilot studies resemble the main
study in many respects [90], they are a smaller version
of the main study that test whether its components can
all work together [91]. They are a requisite initial step in
exploring a novel intervention [92] and resemble the
main study in many respects, including an initial assess-
ment of the primary outcome [93]. The pilot phase
hence ensures that money is not wasted on an expensive
trial which produces a null result due to problems with re-
cruitment, retention or delivery of the intervention [94]
and that end results are more applicable to real-world set-
tings. It was therefore decided to conduct a pilot study
prior to a definitive full-scale effectiveness RCT.
The MRC guidance for process evaluation of complex
interventions [95, 96] advocates the potential value of the
qualitative research in health interventions. This is part of
the growing call to move away from the inappropriate use
of pilot trials as hypothesis testing to a greater emphasis
on their descriptive, feasibility potential [97]. RCTs are
considered the ‘gold standard’ for providing evidence in
decision-making in evidence-based practice [98], yet they
have been criticised for not providing sufficient evidence
that is useful in practice [99]. After the trial, qualitative ap-
proaches can help to explore reasons for the findings,
examine the appropriateness of the underlying theory and
steer researchers towards interventions more likely to be
effective in the future [100]. Furthermore, qualitative
process evaluation supports understanding and explan-
ation of the processes involved during the implementation
of an intervention and its potential integration in everyday
practice [101]. To date, only an estimated 3–8% of trials
have incorporated qualitative research components [102].
The current pilot trial will hence include a nested qualita-
tive component, with interviews with the IBD patients,
the therapist/s delivering the intervention and HCPs
working with patients with IBD. The nested qualitative
component will strengthen the findings by evaluating per-
ceptions of the current pilot intervention and ultimately
enhance the acceptability of the intervention in a large-
scale trial.
Research questions: What is the feasibility of a CBT
intervention for the management of fatigue in patients
with IBD? What are the initial estimates of efficacy of an
intervention for the management of fatigue in patients
with IBD?
Methods and design
This study will assess the feasibility and initial estimates
of efficacy of a CBT intervention for the management of
fatigue in patients with IBD. The pilot intervention will
have the objectives to:
 Assess the feasibility of recruiting eligible patients;
 Assess the willingness of participants to be
randomised;
 Evaluate the compliance rates to the intervention
(Therapist Sessions and Homework Sheets);
 Assess withdrawal and dropout rates during the
treatment phase;
 Assess the completion rates of the outcome
measures post intervention and at follow-up times;
 Determine the adequate sample size for definitive
full-scale effectiveness RCT;
 Obtain initial estimates of efficacy on fatigue and
QoL in the CBT intervention group compared to
the fatigue Information Sheet group;
 Obtain detailed qualitative feedback from patients,
the therapist/s delivering the intervention and HCPs
working with patients with IBD on their experience
and views of the intervention and areas for
improvement in future fatigue interventions.
The pilot trial will not attempt to provide evidence of
clinical effectiveness for the CBT intervention in people
with IBD. This is in accordance with the recommenda-
tions from the National Institute of Healthcare Research
(NIHR) guidelines and the Consolidated Standards of
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Reporting Trials (CONSORT) for the development of
pilot studies [91, 103].
Study design
The study will be a two-arm pilot RCT. Patients will be
recruited from the outpatient IBD clinic at a single
specialist hospital site and randomised individually, using
a 1:1 ratio computerised algorithm. A nested qualitative
study will evaluate patient and therapist experience, and
HCPs perceptions of the intervention. The study will have
a total duration of 22 months with two phases.
Phase 1: the pilot randomised controlled trial (n = 40)
Recruitment
A member of the direct care team at the recruitment site
will look through electronic and paper medical records,
reviewing the inclusion/exclusion criteria, and identify
potentially eligible patients attending the IBD outpatient
clinic that day. Consecutive potentially eligible patients
attending outpatient IBD clinics from January 2017 to
June 2017 will be included in the recruitment process.
At the end of their appointment a direct member of
their care team will ask patients if they would be happy
to be approached by a researcher to take part in a
research study. If the patient is interested, they will then
be directed to the research room. A member of the re-
search team will hand the patients a Patient Information
Sheet (PIS) and provide them with a full verbal explan-
ation of the RCT. Patients will be given adequate time to
fully comprehend the content of the PIS and will be
given the opportunity to ask questions about taking part
in the study. Those who indicate a potential interest in
the RCT will be screened for full eligibility using the
Eligibility Screening Form. If ineligible, the patient will
be thanked for their interest, will not be enrolled in the
study and no personal details will be recorded.
Eligible patients will then be given at least 48 h to
consider their participation in the study and discuss the
decision with family, friends and their care team. A
member of the research team will then contact them by
telephone to answer any additional questions, verify
their understanding of what is involved and confirm
their interest in study participation. If patients agree to
take part in the study, they will be asked to sign the
Patient Consent Forms-RCT and complete the Baseline
Data A booklet. A format for written questions for this
phase has been developed and piloted with our PPI
group to ensure acceptability and ease of understanding
of questions to be asked. Participants will be asked to
return the signed Patient Consent Forms-RCT and the
completed questionnaires in the pre-paid stamped
addressed envelope provided within seven days of re-
ceipt. The returned study documents will be checked for
completeness, and the patient will then be entered into
the randomisation database for the RCT and told whether
they are in Group 1 (CBT manual + therapist support) or
Group 2 (Fatigue Information Sheet only). Screening and
consenting will continue until the study target sample size
(n = 40, 20 for each arm) is reached. Hospital consultants
will be informed of the patients’ participation in the study
via an entry made in the patient’s notes; with patients’
agreement, their General Practitioner (GP) will be informed
using GP Notification Letter.
Randomisation
Consenting participants will be randomised to CBT
manual plus therapist support or Fatigue Information
Sheet only using a random number generator with a 1:1
ratio in the Statistical Package for the Social Sciences
Version 22. All baseline information will be collected
prior to randomisation. Participants will be randomised
at the individual level. The randomisation sequence will
be generated electronically by an independent statisti-
cian prior to the commencement of the study. The
statistician will have no patient contact. The trial coord-
inator (blinded until this point) will access the random-
isation database to assign patients to the two groups.
Indeed, as this is a small pilot study on a limited budget,
there are no resources available to provide a blinded
data collector. Owning to the nature of the study the
participants, the researchers and the therapist will not
be blinded to treatment allocation after randomisation.
The trial coordinator will be informed of the outcome of
the randomisation procedure in order to identify partici-
pants who require telephone support calls during the
trial. The researcher conducting the qualitative inter-
views will also be unblinded to ensure that appropriate
questions are asked.
Group 1 (CBT manual + therapist support)
Group 1 participants will receive a CBT manual for the
management of fatigue and have one 60-min session and
seven 30-min telephone/Skype sessions with a therapist
over an eight-week period. All sessions will be over the
telephone or Skype according to patient preference. In
the Consent Form, patients will be informed that if they
choose Skype, information may not be secure and may
be transferred to other countries outside the Trust’s
control. During the intervention, participants will have
access to all usual care, including the nurse-led helpline.
CBT manual development
The CBT manual utilised for the intervention will be a
modification of the CBT manual for the management of
MS fatigue developed by Van Kessel et al. [57]. The
manual contains eight sessions. Despite, the lack of
consensus from systematic reviews on the adequate
number of therapy sessions to be used by interventions,
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the number of sessions was modelled on the number of
sessions utilised in the RCT by Van Kessel et al. [57],
where 100% of the subjections in the CBT group com-
pleted the eight-session intervention with large effect
sizes. The sessions include: IBD fatigue explained; CBT
for IBD fatigue; activity scheduling; improving your
sleep; understanding IBD symptoms; changing your
thinking; managing stress, determining a sense of con-
trol and coping with emotions; social support and pre-
paring for the future, and it has an approximate length
of 100 pages. One of the authors (Rona Moss-Morris) of
the original CBT manual for MS helped in making the
initial changes and refinements to the manual incorpor-
ating evidence from the first MS trial [57] and its adap-
tation into an Internet-based CBT self-management
programme for fatigue in MS [104].
In order to make the intervention relevant and accept-
able to patients with IBD, we have worked with people
with IBD-fatigue, consultant gastroenterologists, IBD-
nurse specialists, dieticians and psychologists working
with people with IBD. Specifically, Session 1 of the inter-
vention manual ‘IBD-Fatigue Explained’ addresses med-
ical factors causing fatigue which are specific to patients
with IBD including inflammation and fatigue and an-
aemia and fatigue. Furthermore, examples and tasks
throughout the intervention manual have been adapted
to reflect concerns and issues specific to patients with
IBD and not MS. Finally, a medical writer conducted in-
depth pre-post readability statistics and performed the
required changes to transform the intervention manual
into plain English and make the language as clear as
possible. Likewise, a graphic designer made the neces-
sary formatting edits to the manual so as to make the
design more user-friendly.
Therapists
Patients will have telephone support sessions with one of
two qualified CBT therapists who have experience in
delivering interventions to patients with long-term condi-
tions. The therapist will receive the manual in advance
and have the opportunity to discuss its contents and any
questions with the research team. The purpose of the tele-
phone/Skype support calls are to promote engagement
with the intervention and to support the patient in collab-
oratively developing goals to work on using the resources
and information available to them in the CBT manual. At
the start of each telephone call, the therapist will set an
agenda with the participant. The first telephone/Skype
support call will be scheduled for when the participant will
have completed the first session in the CBT manual.
Group 2 (Fatigue Information Sheet only)
Group 2 participants will receive the Crohn’s and Colitis
UK (CCUK) ‘Fatigue in IBD’ Information Sheet to use
without therapist help. CCUK is the UK’s leading charity
for patients with CD and UC. CCUK provides patients
with free online information sheet and guides to help
those affected by IBD. As many people with IBD suffer
from fatigue, CCUK, together with our research team
(CN, WCD), developed an Information Sheet which ex-
plains what fatigue is, what may cause it and possible
ways of reducing it.
Feasibility and acceptability outcomes
Feasibility of recruiting eligible patients will be evaluated
by calculating the proportion of those invited to take
part in the intervention that were eligible and then were
consented into the trial. The willingness of participants
to be randomised will be evaluated by calculating the
proportion of those who dropped out of the trial after
they have been randomised. Refusal, withdrawal and
dropout rates from the study and number of sessions
with therapist will be recorded. A post-intervention
follow-up questionnaire included in Outcome Data B
booklet will assess compliance rates to the intervention
by asking participants about the number of sessions of
the manual they read and time per week spent complet-
ing tasks in relation to the intervention. The therapist/s
will also record how many sessions the participants have
completed. Furthermore, in order to assess compliance
to the intervention procedures, if participants are willing
to do so, they will be asked to provide the research team
with the Homework Sheets completed at the end of each
session in the manual. The Homework Sheets will be
checked for completion in order to assess compliance
with the intervention components.
Initial estimates of efficacy outcomes
Prior to randomisation, eligible participants will complete
the study baseline measures which are contained in a
single questionnaire booklet. The questionnaire booklet
contains 20 printed pages. Preliminary piloting has dem-
onstrated that on average it has taken 10–15 min to
complete and our patient representatives have commented
that this is not unduly burdensome. Three months post
randomisation, the Outcome Questionnaire booklets will
be sent by post. Patients who were allocated to the CBT
intervention and will be asked further questions about
their experience of completing the intervention in order
to assess their compliance with the intervention, prefer-
ences, acceptability and satisfaction with the intervention.
Patients who were allocated to Fatigue Information Sheet
only, will be asked about their experience of reading the
Fatigue Information Sheet. A postal reminder will be
sent to non-responders two and four weeks after the
seven-day response period has ended, utilising the
Reminder Letter and/or a telephone call. Six and
12 months post randomisation, two more outcome
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booklets will be sent respectively, with two postal reminders
and/or telephone calls for non-responders after two and
four weeks. The booklets will only contain the primary
outcome measures IBD-fatigue, QoL UK questionnaire and
Disease Activity Indexes (DAIs) specific to the condition.
Twelve months post randomisation
Patients in the Fatigue Information Sheet only group
(Group 2) will be offered the CBT manual for managing
fatigue in IBD. No therapist support will be offered
alongside the manual.
Nested qualitative study (n = 7 patients + both ther-
apist/s + approximately three HCPs)
To better understand patient perspectives on the inter-
vention, participants consenting to the RCT might be
invited for interview. The interview sub-sample will be
purposively selected to include both genders, a range of
ages, both IBD diagnoses and those successful and not
successful in showing an initial improvement in IBD-
fatigue. Purposive sampling has the potential to provide
richer, more relevant and diverse data pertinent to the
research question [105, 106]. Participants will be asked
about the process of recruitment and randomisation,
their experience of the intervention itself, their reasons
for dropping out or not completing (where appropriate)
and areas for improvement in the design of future fa-
tigue interventions for patients with IBD. Patients will
receive information about the interviews in the Patient
Information Sheet – RCT and Interviews. Using the
Patient Consent Form – Interviews, separate informed
consent will be sought for the face-to-face/telephone/
Skype, semi-structured interviews with a purposive sam-
ple of approximately seven participants (about one-third
of the participants in Group 1). Interviews will be con-
ducted by a researcher not involved in the delivery of
the intervention and have a duration of 30–60 min.
The nested qualitative study will be conducted after the
three-month follow-up quantitative data collection point.
The choice of qualitative data collection at three months
allows for minimisation of recall bias, patient burden and
confounding of participants in the study. The short time
period between the intervention and the interviews,
ensures that participants will find it easier to recall their
experience of the intervention. Indeed, involvement in
qualitative data collection as part of an RCT may in some
way influence the participant’s experience of treatment
[107]. However, the gap in time between the interviews
and the next follow-up data collection point (six months
post randomisation) limits the potential for participants’
outcome responses to be influenced by their participation
in the interviews. Furthermore, time gap in time between
interviews and follow-up questionnaire completion re-
duces potential patient burden, while still ensuring
continuity to the study.
The therapists supporting patients during the interven-
tion will be interviewed to understand their experience of
delivering the intervention and to inform future adapta-
tion and delivery of the intervention in clinical practice.
HCPs working with patients with patients with IBD at the
study site will be interviewed to obtain their views on the
intervention and its possible implementation within
existing IBD service at a roll out stage. Approximately
three HCPs will be interviewed. Informed consent for
the interview will be secured using the Staff Consent
Form – Interviews.
Qualitative analysis
Interviews will be conducted by a researcher who will not
be involved in the delivery of the intervention. Interviews
will be digitally audio-recorded, anonymised and tran-
scribed verbatim by a professional transcriber. Original
audio files and file transcripts will be stored on a secure
server at King’s College London (KCL) in a password
protected file. The transcriber will delete his/her copy of
each audio file once transcription is complete. Data will be
analysed using thematic analysis [108] and, if appropriate,
NVivo11 software for data management. Analysis begins
with a coding framework, where key concepts emerging
from the transcripts will be mapped. Additional themes
emerging are added to the coding framework. The final
framework is agreed, then applied to all transcripts. An
iterative process will confirm a final coding framework
before analysis. Two researchers will code all transcripts
independently and then compare and refine resulting
codes and themes in discussion. The emergent themes will
form the basis of analytical interpretation. Process evalu-
ation data will be analysed separately from outcome data
in order to avoid bias in interpretation [109].
Study outcome measures
For feasibility and acceptability outcomes, please refer to
Study outcome measures. The primary and secondary out-
come measures will be recorded at baseline, three, six and
12 months post randomisation. The primary outcome
measure will be utilised to assess initial estimates efficacy
of the intervention in the CBT intervention group com-
pared to the Fatigue Information Sheet group. All out-
come measures have been validated for self-completion.
Primary outcome measure
IBD-Fatigue Scale (IBD-F)
The IBD-F [110] aims to assess IBD-specific fatigue. The
first two sections of the questionnaire, five questions
assessing frequency and severity of fatigue and 30 ques-
tions rating the experience and impact of fatigue, will be
utilised in the study. Higher scores indicate higher fa-
tigue and higher impact of fatigue. Initial validation of
the measure suggested that the questionnaire had good
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face and content validity, acceptable to excellent test–
retest stability and a high degree of internal consistency
[110]. Both sections of the IBD-F have been found to
be significantly correlated with other widely utilised fa-
tigue scales [22]. The scale was developed by conducting
in-depth interviews with participants with IBD, in order to
gain insight into their experience and ultimately to
represent issues of specific importance to people with
IBD fatigue.
Secondary outcome measures
United Kingdom Inflammatory Bowel Disease Questionnaire
(UK IBDQ)
The UK IBDQ [111] is the British version of the
McMaster IBDQ [112]. It has 32 items, each scored in
the range of 1–4, with a summary score between 30 and
120. A low score indicates poor quality of life. Initial
findings have supported the reliability, validity, reprodu-
cibility and responsiveness of the UK version of the
questionnaire. The questionnaire has been found accept-
able to patients in the UK. It enhances the precision of
some of the questions in the McMaster IBDQ, improves
the readability of the questionnaire, removes items that
do not provide useful information and simplifies the
response categories. The IBDQ was developed with pa-
tients with IBD, it therefore reflects the concerns of the
patients themselves about the impact of their disease on
their life-style and quality of life. The IBDQ is recom-
mended for use in healthcare evaluation to assess the
effect of interventions for IBD on QoL [113]. Members
of our patient representatives group voted 15:2 in favour
of the UK version when compared with the original
version, stating ‘choices more straightforward’.
Explanatory variables
Disease activity indexes
The Harvey Bradshaw Index (HBI) [114] and the Simple
Clinical Colitis Activity Index (SCCAI) [115] will be uti-
lised to measure disease activity for CD and UC patients,
respectively. The HBI and SCCAI will be recorded at
baseline, three, six and 12 months post randomisation.
All other explanatory variables will only be recorded at
baseline and three months post randomisation.
Brief Illness Perceptions Questionnaire (BIPQ)
The BIPQ [116] uses a single-item scale approach to
assess illness perceptions. It is a shorter version of the
original Illness Perception Questionnaire (IPQ) [117]
which is utilised to assess five dimensions within a
cognitive representation of illness. The brief version
consists of nine items: five of the items assess cogni-
tive illness representations (consequences, timeline,
personal control, treatment control and identity), two
of them assess emotional representation (concern and
emotions) and one item assesses illness comprehen-
sibly. Each item (e.g. ‘How concerned are you about
your fatigue?’) is rated using a response scale of 0–10; in
which higher scores represent more threatening views of
fatigue. The psychometric properties of this measure have
been assessed using samples from several illness groups
including IBD [118] and chronic obstructive pulmonary
disease [119].
Epworth Sleepiness Scales (ESS)
The ESS [120] is utilised to measure a participant’s level
of daytime sleepiness. From a clinical point of view this
is relevant in that it helps to determine the presence of
pathology or simply predict whether sleep onset is likely
to occur at inappropriate times [121]. The questionnaire
asks participants to rate their chance of falling asleep or
dozing on a scale of 0–3 in eight soporific situations,
ranging from ‘Lying down to rest in the afternoon when
circumstances permit’ to ‘in a car while stopped for a
few minutes in traffic’. A total score of 0–24 is deter-
mined, with values over 10–11 indicating abnormal or
pathological sleepiness. Given its ease of use and cost-
effectiveness, the ESS in now one of the most widely
used tools for the assessment of sleepiness [122].
Seven-item Generalised Anxiety Disorder Scale (GAD7)
The GAD7 [123] asks participants how often during the
last two weeks they have been bothered by each of the
seven core symptoms of generalised anxiety disorder.
Response options are ‘not at all’, ‘several days’, ‘more than
half the days’ and ‘nearly every day’, scored as 0, 1, 2 and
3, respectively. It has a minimum possible score of 0 and
a maximum possible score of 21. The GAD7 has been
utilised in studies assessing anxiety severity in diverse
conditions, including: patients with eating disorders [124];
multiple sclerosis [125]; and cardiovascular disease [126].
The GAD7 is used as an outcome measure for CBT for
anxiety in the UK Improving Access to Psychological
Therapies (IAPT) programme [127].
Nine-item Patient Health Questionnaire (PHQ9)
The PHQ9 [128] is based on the diagnostic criteria for
major depressive disorders in the Diagnostic and Statis-
tical Manual, Fourth Edition (DSM-IV). The questionnaire
contains nine items, which are scored from 0 (not at all)
to 3 (nearly every day), according to the frequency of their
experience over the previous two-week period, with a total
score in the range of 0–27. The PHQ9 has been found to
be a reliable and valid measure [129] and it has been
previously validated in gastroenterological patients [130].
The PHQ9 is used as an outcome measure for CBT for
depression in the IAPT programme.
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Sociodemographic and clinical data
Sociodemographic and clinical data about participants
will be collected at baseline in order to better character-
ise the sample, make the results of the RCT more clinic-
ally relevant and appropriately adjusting statistical data
analysis. Sociodemographic data collected will include:
age; gender; marital status; education status; employ-
ment status; and living arrangements. Clinical data will
include: IBD diagnosis; co-morbidities; latest measure-
ment of faecal calprotectin concentration; IBD-related
medications (name, dose and frequency); length of time
since diagnosis (years, months); number of IBD-related
surgeries; smoking status (current smoker, ex-smoker,
never smoked); exercise status (> or < 30 min of aerobic
exercise per week); haemoglobin; ferritin; serum
albumin; C-reactive protein (CRP); platelets count;
vitamin B12; and folate. These clinical data are routinely
collected as part of standard care in patients with IBD at
these sites. If the patient does not attend the service at
follow-up, it is unknown whether there will be updated
clinical data for patients. However, due to potential
patient burden and lack of funding, no additional blood
tests will be conducted for the patients, even if recent
clinical data are not present in the hospital patient
records. One value for each clinical marker will be
collected if it refers to up to three months prior to or
after the completion of the baseline questionnaires.
Participant entry
Patient interviewees will be selected from those recruited
for the RCT, who will have been evaluated prior to
enrolment. The Eligibility Screening Form will be used
to conduct pre-registration evaluation of participants
for the RCT.
Inclusion criteria
 Patients who are currently experiencing fatigue
(self-reported)
 Proof of diagnosis of IBD (record of diagnostic
endoscopy in patient clinical notes); patients without
this test will not be included
 Aged 18 years and over
 No elevated inflammatory markers or other clinical
features of active disease
Exclusion criteria
 Patients without a record of diagnostic endoscopy in
their clinical notes
 Elevated inflammatory markers or other clinical
features of active disease
 Course of CBT for any reason in the last year
 Currently enrolled in another trial involving a novel
pharmacological intervention
 Current or planned pregnancy (pregnant women
have been found to be significantly more affected by
fatigue and sleep disturbances [131])
 Inability to give informed consent (for example, due
to reduced mental capacity)
 Insufficient command of written and spoken English
to understand study documents or procedures
Statistics and data analysis
Due to the pilot design of the study a power calculation
was not required. Data collected in the pilot study will
be used to generate information for sample size calcula-
tions for a definitive full-scale effectiveness RCT. Based
on similar pilot studies, a sample of 40 patients (20 per
arm) was deemed large enough to provide useful infor-
mation about the aspects that are being assessed for
feasibility. It is recognised that the study may not be
powered to detect meaningful differences in clinically
important endpoints [91].
Patients will be recruited from an IBD outpatient
clinic in London, UK, which is representative of the
target study population of patients experiencing IBD-
fatigue. The sample was based on the same inclusion/
exclusion criteria that would be used in a future defini-
tive full-scale effectiveness RCT. At the study site, a total
of approximately 100–150 patients attend four IBD out-
patient clinics each week. Assuming around 40% recruit-
ment of eligible patients based on our earlier studies
recruiting from this population [83], discussions with
the clinical team and recruitment rates for intervention
for fatigue in MS [57], our target aim of 40 patients
should be reached within the six-month baseline data
collection period. Taking into account an attrition rate
based on prior research [132] of about 20% for each
follow-up, we will aim to achieve a minimum sample size
of 40 at baseline, in order to suitably assess outcomes at
follow-up.
Primary and secondary measures at baseline along
with recruitment rates, telephone session attendance,
time spent on the intervention, Homework Sheet com-
pletion rates and withdrawal from intervention rates will
be presented as means and standard deviations for ap-
proximately normally distributed continuous variables,
medians and interquartile ranges for non-normally
distributed variables, frequencies and percentages for
categorical variables. Initial estimates of treatment effect
on primary and secondary outcomes at the follow-up
assessments will use an intention-to-treat (ITT) frame-
work, implemented using a regression model, adjusting
for baseline values of the outcome, sociodemographic
and clinical outcomes. ITT analysis will compare the pri-
mary and secondary outcome measures at three months
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between the two randomised groups. ITT analysis will
compare only primary outcome measures at six and
12 months between the two randomised groups. Where
participants wish to withdraw from the intervention, we
will attempt to retain them in the data collection, unless
they express a wish to be withdrawn completely.
As this is a pilot study, it is not intended that the study
is powered to detect significant differences on the primary
or secondary outcome measures. Qualitative data will also
be recorded. Protocol conforms to Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT). See
Additional files 1 and 2 at the end of the manuscript for
SPIRIT Figure and Checklist.
Discussion
This is the first RCT to utilise CBT for the management
of fatigue in patients with IBD. To date, psychosocial
interventions utilising problem-solving, solution focused
therapy (SFT; 42, 44) and stress management [52] have
shown promising effects. However, their effects declined
over time [44] and fatigue was not always the primary
outcome of the intervention [52]. The study will provide
evidence of the feasibility and initial estimates of efficacy
of a CBT intervention for the management of fatigue in
patients with IBD. Quantitative and qualitative findings
from the pilot study will contribute to the development and
implementation of a subsequent large-scale RCT assessing
the efficacy of CBT interventions for IBD-fatigue.
One of the limitations of the pilot trial is the small
number of participants which will impact on the statis-
tical strength of the study. However, the lack of sufficient
data about the feasibility and efficacy of CBT for the
management of fatigue in this population necessitates
the undertaking of an initial pilot upon this issue.
Trial status
Patient recruitment for the study will begin in January
2017 and is expected to continue for six months in total.
Additional files
Additional file 1: SPIRIT Checklist. (DOC 104 kb)
Additional file 2: SPIRIT Figure. (DOC 61 kb)
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